Bone marrow mesenchymal stem cells modified pathological changes and immunological responses in ovalbumin-induced asthmatic rats possibly by the modulation of miRNA155 and miRNA133

Abstract

In the current experiment, we investigated the immune-modulatory potential of mesenchymal stem cells (MSCs) and conditioned media (CM) in attenuating of chronic asthmatic changes in a rat model. Male rats were divided into control (C) and ovalbumin-sensitized (S) groups, which further allocated into three subgroups; rats received systemically 50 μl volume of PBS (C and S groups), CM (CSV and SSV groups) and rats received intravenous infusion of 2 × 106 bone marrow-derived mesenchymal stem cells (rBMMSCs) (CCV and SCV groups). Two weeks later, the expression of interleukin (IL)-4, IL-13, and IL-10, miRNA133, and miRNA155 was measured by real-time PCR. Pathological changes and the recruitment of rBMMSCs into pulmonary parenchyma were evaluated by histopathological and immunofluorescence analyses, respectively. The systemic injection of rBMMSCs, but not CM, decreased the levels of IL-4, IL-13, IL-10, miRNA133, miRNA155 and reduced pathological changes in sensitized rats as compared with other sensitized groups (p < 0.001 to p < 0.05). rBMMSCs transmigrated to lung tissue in cell-administrated rats, albeit intensity of asthmatic changes, in turn, affected the amount of recruited cells. Collectively, our data suggest the potential role of MSCs, but not CM, in reducing pathological changes possibly via the modulation of miRNA133 and miRNA155 during asthmatic changes.

Intratracheal administration of bone marrow c-kit+ cells offered hopes in ameliorating asthmatic pathologies via the control of miRNA-133 and -126

“…We used a protocol a period of 32 ± 1 days for induction of asthmatic changes according to our previous experiment [2]. For this propose, rats were received 1 ml sterile normal saline containing 1 mg ovalbumin (Sigma -Aldrich, USA) and 200mg aluminum hydroxide intraperitoneally on days 1and 8.…”

“…Despite advantages in human medicine, there are some pathological conditions without de nite evidence of therapeutic approach. Among them, asthma is highly prevalent in all parts of the world, ranging from 0.2 to 21.0%, with considerable healthcare costs [1,2]. The current strategies on asthmatic subjects rely on the modulation of in ammatory responses by the application of pharmacological agents.…”

“…The current strategies on asthmatic subjects rely on the modulation of in ammatory responses by the application of pharmacological agents. However, these agents are not applicable for a long period and conceived as a symptomatic treatment to alleviate or suppress asthmatic attacks due to commonly reported side effects and ine ciency to alleviate an aberrant remodeling [2,3]. Therefore, researches targeting pathogenesis and treatment protocols have been a hot topic in the context of asthmatic milieu.…”

“…According to previous experiments, these genetic elements could be used as biomarkers for the detection different pathologies [14,15]. Even though, the modulating effect of miRNA should be determined to control immune-mediated in ammatory responses [2,13,15]. Previously, the critical role of both miRNA-126 and miRNA-133 has been diagnosed in animal asthma models.…”

The effect of alginate-gelatin encapsulation on the maturation of human myelomonocytic cell line U937

“…In healthy adults, bone marrow niche provides three‐dimensional (3D) dynamic microenvironment with the participation of extracellular matrix (ECM) and stromal cells (Ogawa, ). It has been reported that bone marrow is the main location for haematopoietic stem cells (HSCs) and mesenchymal stem cells and common progenitors of all blood cell types (Ahmadi, Rahbarghazi, Shahbazfar, Baghban, & Keyhanmanesh, ; Ogawa, ). Along with other conventional modalities, transplantation of whole bone marrow content, specific progenitors, or HSCs is touted as a potentially life saving and curative therapeutic approach in patients with bone marrow disorders (Ulloa‐Montoya, Verfaillie, & Hu, ).…”